Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained
Stock Performance: Wild Swings from Deaths to Resumption SRPT has been a roller-coaster. In early 2025, Sarepta’s shares were largely pummeled by the DMD gene-therapy crisis. After two Duchenne patients (non-ambulatory teens) died in June and FDA urged a full pause, the stock plunged to decade lows (losing ~85% YTD) nasdaq.com biospace.com. (William Blair analysts warned this was a “worst-case scenario” that could “negatively affect patient interest in Elevidys” biospace.com.) On July 17, Sarepta partially paused Elevidys for all patients, and FDA did as well – shares briefly hit the low teens. Then, on July 28 FDA green-lit Elevidys resumption